Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-1 in Advanced Solid Malignancies
NCT03138083Phase 2Terminated
- Sponsor
- OCTIMET Oncology
- Start
- Aug 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of JNJ-38877618 in solid tumor, sponsored by OCTIMET Oncology. Started Aug 2017; status: terminated.
02
Drugs
JNJ-38877618
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03138083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138083.